Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Risk genes beyond APOE

Topic: Inflammation, microglia and astrocytes

Utilizing β-amyloid precursor protein (βAPP) as a substrate, α-, β-, and γ-secretases are responsible for sequential cleavage events leading to the formation of β-amyloid, the classic pathologic hallmark of Alzheimer’s Disease. Members of this class of proteases also catalyze the activation of numerous other membrane-localized proteins implicated in cell growth and neuroinflammation such as NOTCH and the Interleukin/TNF-receptor family, respectively. This investigation addresses if an in vitro Chlamydia pneumoniae infection of human astrocytes affects the processing of βAPP through modifying the protein expression of the following βAPP processing proteases: A Disintegrin and Metalloproteinase-10 (ADAM10), βAPP cleaving enzyme-1 (BACE1), and presenilin-1 (PSEN1). Human astrocytoma cells (CCF-STTG1) were infected in vitro with Chlamydia pneumoniae strain AR39 (MOI=1). At 6-72 hours post infection, protein level of β-amyloid, ADAM10, BACE1, and presenilin-1 N-terminal fragment (NTF) relative to uninfected controls were detected by immunofluorescence and quantified by western blot analysis. Cytoplasmic labeling of Aβ1-42 was increased in infected cells relative to that of uninfected cells. Membrane-localized labeling of BACE1 and cytoplasmic labeling of PSEN1 NTF was also enhanced at earlier (6 hrs.) and later (48/72 hrs.) time points post infection relative to that of uninfected astrocytes. Increases in quantified BACE1 and PSEN1, but not ADAM10, followed a similar temporal increase most notable at 48 hrs. post infection. These data indicate that infection of human astrocytes with Chlamydia pneumoniae strain AR39 promotes the processing of βAPP characteristic of Alzheimer’s Disease through enhancing BACE1 and PSEN1, but not ADAM10, protein levels. Increases in active secretase protein may coincide with the 24-48 hr. lifecycle of Chlamydial intracellular growth and replication and the consequent astrocytic inflammatory response.

Key findings

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multi-centre collaboration left out, no data; Indexed in PubMed 1 of 2; Free to read 2 of 2. 22 of the 58 points it could be judged on, which is 38 of 100. Total 38 of 100.22 of the 58 points we could judge = 38 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 22 of the 58 points we could judge it on, which is 38 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2016 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 22 / 58 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 22 of the 58 points we could judge it on is 38 out of 100.
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Al-Atrache, Z., Cader, A., & Appelt, D. M. (2016). P1‐146: Chlamydia Pneumoniae‐Infected Astrocytes Alter Their Expression of Adam10, Bace1, and Presenilin‐1 Proteases. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2016.06.894

Vancouver

Al-Atrache Z, Cader A, Appelt DM. P1‐146: Chlamydia Pneumoniae‐Infected Astrocytes Alter Their Expression of Adam10, Bace1, and Presenilin‐1 Proteases. Alzheimer s & Dementia. 2016. doi:10.1016/j.jalz.2016.06.894.

BibTeX

@article{alatrache2016-51ba2d77,
  author  = {Al-Atrache, Zein and Cader, Ahmad and Appelt, Denah Marie},
  title   = {{P1‐146: Chlamydia Pneumoniae‐Infected Astrocytes Alter Their Expression of Adam10, Bace1, and Presenilin‐1 Proteases}},
  journal = {Alzheimer s \& Dementia},
  year    = {2016},
  doi     = {10.1016/j.jalz.2016.06.894},
  url     = {https://doi.org/10.1016/j.jalz.2016.06.894}
}

Related studies in Risk genes beyond APOE

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →